Otsuka Pharmaceutical Development & Commercialization, Inc.
Clinical trials sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., explained in plain language.
A subsidiary of Otsuka Holdings, focused on developing and commercializing pharmaceutical products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug VIS171 enters human trials for lupus, hair loss, and kidney disease Results expected Oct 2026 (estimated)
- New schizophrenia pill shows promise in major trial Results expected Oct 2026 (estimated)
- New drug interaction study launches for repinatrabit Results expected Nov 2026 (estimated)
- Study aims to tailor PKU drug dosing for patients with organ impairment Results expected Feb 2027 (estimated)
- New shot could tame Sjögren's Flare-Ups Results expected Mar 2027 (estimated)
-
Can a new daily pill offer lasting relief for anxiety?
Disease control Not yet recruitingThis trial is testing the long-term safety and tolerability of an investigational drug called SEP-363856 (ulotaront) in adults with generalized anxiety disorder (GAD). Participants who completed a previous phase 3 study will take the drug daily for 26 weeks. The study will monito…
Phase 3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a new injection slow kidney disease in children?
Disease control Not yet recruitingThis phase 3 trial is testing whether sibeprenlimab, an investigational drug given as an injection every 4 weeks, can help children and adolescents with IgA nephropathy. The study includes about 24 participants aged 2 to 17 with biopsy-confirmed disease. The main goal is to see i…
Phase 3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug HBM7020 tested in humans for first time against autoimmune diseases
Disease control Not yet recruitingThis first-in-human study tests the safety of a new drug called HBM7020. It will first be given to healthy volunteers at low doses, then to people with moderate to severe autoimmune diseases like lupus, rheumatoid arthritis, scleroderma, and Sjögren's disease. The goal is to see …
Phase 1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Tiny study tracks experimental schizophrenia Drug's journey in healthy men
Knowledge-focused Not yet recruitingThis early-stage trial will give 8 healthy men a single dose of a radioactive-labeled experimental drug called SEP-380135, which is being developed for schizophrenia. The goal is to track how the drug is absorbed, broken down, and eliminated from the body. This study does not tes…
Phase 1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC